Hypouricemic and nephroprotective effects of palmatine from Cortex Phellodendri Amurensis: a uric acid modulator targeting Keap1-Nrf2/NLRP3 axis

G Ai, R Huang, J Xie, L Zhong, X Wu, Z Qin, Z Su… - Journal of …, 2023 - Elsevier
Abstract Ethnopharmacological relevance Palmatine (Pal) is a major bioactive alkaloid
originated from ancient Chinese herbal medicine Cortex Phellodendri Amurensis (CPA) …

New rice-derived short peptide potently alleviated hyperuricemia induced by potassium oxonate in rats

N Liu, Y Wang, M Yang, W Bian, L Zeng… - Journal of Agricultural …, 2018 - ACS Publications
Gout that caused by hyperuricemia affects human health seriously and more efficient drugs
are urgently required clinically. In this study, a novel peptide named RDP1 (AAAAGAKAR …

Enhanced oral bioavailability and anti-gout activity of [6]-shogaol-loaded solid lipid nanoparticles

Q Wang, Q Yang, X Cao, Q Wei, CK Firempong… - International journal of …, 2018 - Elsevier
Shogaol, an alkylphenol compound purified from the root and stem of ginger (Zingiber
officinale), has attracted considerable interest due to its potential anticancer, antioxidative …

Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients

CJ van de Laar, CA Janssen, M Janssen… - PloS one, 2022 - journals.plos.org
Objectives To assess the cost-effectiveness of various combinations of urate lowering
therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout …

Uric acid-lowering effect of harpagoside and its protective effect against hyperuricemia-induced renal injury in mice

Q Fu, JJ Zhang, QF Zhu, LL Yu, F Wang, J Li… - Biochemical and …, 2024 - Elsevier
Hyperuricemia (HUA) is caused by increased synthesis and/or insufficient excretion of uric
acid (UA). Long-lasting HUA may lead to a number of diseases including gout and kidney …

Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients

M Presa, F Pérez-Ruiz, I Oyagüez - Clinical Rheumatology, 2019 - Springer
Introduction/objectives Lesinurad, in combination with allopurinol, has been approved for
treatment of patients with gout which do not reach therapeutic serum urate target with …

Lesinurad in hyperuricaemia of gout: a profile of its use in the EU

HA Blair, ED Deeks - Drugs & Therapy Perspectives, 2018 - Springer
Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA
production. The selective UA reabsorption inhibitor lesinurad (Zurampic®) is an effective …

[PDF][PDF] Celine J. van de Laar, Carly A. Janssen, Matthijs Janssen, Martijn AH Oude Voshaar

MJ Al - GOUT: PATIENTS, MEDICINE AND SOCIETY - ris.utwente.nl
Objectives. To assess the cost-effectiveness of various combinations of urate lowering
therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout …

Allopurinol/lesinurad cost effective for gout/hyperuricaemia

M Ruggeri - PharmacoEconomics & Outcomes News, 2018 - Springer
Allopurinol/lesinurad appears to be cost effective for the management of gout or
hyperuricaemia in Italy, according to findings of a Grunenthal Italia-funded study published …